Table 1. Baseline characteristics in 50 patients with unresectable, chemotherapy-refractory CRC liver metastases treated with 90Y hepatic artery radioembolisation.
| Characteristic | |
|---|---|
| Age (years): mean; median (range) | 64; 67 (34–85) |
| Sex: n (%) | |
| Male | 37 (74) |
| Female | 13 (26) |
| Primary tumour site: n (%) | |
| Colon | 41 (82) |
| Rectum | 9 (18) |
| Interval from mCRC diagnosis to radioembolisation (months): mean; median (range) | 19; 17 (6–71) |
| WHO performance status | |
| Median (range) | 0 (0–3) |
| 0 | 35 (70) |
| 1 | 14 (28) |
| 2 | 0 (0) |
| 3 | 1 (2) |
| Haemopoietic function, medians | |
| Haemoglobin, g per 100 ml | 11.40 |
| Leucocytes, × 103 per mm3 | 3.95 |
| Neutrophils (%) | 66.30% |
| Platelets, × 103 per mm3 | 285 |
| Total bilirubin, mg per 100 ml | 0.92 |
| Albumin, g per 100 ml | 3.80 |
| ALT, U l−1 | 55 |
| AST, U l−1 | 58 |
| ALP, U l−1 | 486 |
| INR | 1.06 |
| Prior resection: n (%) | |
| Extra-hepatic | 11 (22) |
| Hepatic | 12 (24) |
| Prior chemotherapy lines: n (%) | |
| Three | 12 (24) |
| Four | 25 (50) |
| Five | 13 (26) |
| Prior bevacizumab: n (%) | 11 (22) |
| Prior cetuximab: n (%) | 5 (10) |
| Liver involvement: n (%) | |
| <25% | 20 (40) |
| 25–50% | 30 (60) |
| Number of metastases: n (%) | |
| ⩽4 | 21 (42) |
| >4 | 29 (58) |
| Bilobar/unilobar: n (%) | 35/15 (70/30) |
| Synchronous/metachronous: n (%) | 36/14 (72/28) |
| Median size of metastases: mm (range) | 50 (8–120) |
Abbreviations: ALP=Alkaline phosphatase; ALT=Alanine transaminase; AST=Aspartate transaminase; INR=Ratio of prothrombin time to normal; mCRC=metastatic colorectal cancer; WHO=World Health Organization.